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with final appeal results were included in the study. The appeals were grouped under 
broader disease area categories and the appeal decision materials were reviewed. 
The grounds of appeals and outcomes of each appeal were extracted. Summary 
statistics were used to present the number of rejected or upheld appeals. Results: 
The most common area of NICE appeals is oncology followed by rheumatology and 
respiratory diseases. More than 50% of the total appeals were lodged in oncology in 
which 30% were breast cancer. The majority of the appeals identified were dismissed 
by the appeal panel on all grounds submitted, whilst approximately a third of the 
appeals were upheld on individual points. ConClusions: The majority of appeals 
submitted to NICE have been rejected by the appeal panel on all grounds. This study 
has only summarized outcomes from NICE appeals, further analysis is required to 
assess factors that influence whether appeals are upheld.
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objeCtives: The EMA has in place evolving guidelines on biosimilars since 2005. 
Biologics Price Competition and Innovation Act (BPCIA) passed by the US Congress 
in 2009 brought focus on biosimilars in the US. The impending expiration of patents 
for many top-selling biologics has also made biosimilars commercially exciting. This 
research evaluates the national and local market access challenges facing biosimi-
lars in the short to medium term. Methods: Formal current positions from HTA 
bodies like NICE, SMC, AWMSG, as well as positions at a national level from payers in 
the NHS in England, Scotland, and Wales, where available, are reviewed to inform the 
national market access situation. Local market access considerations like focus on 
budgets, pricing, discounts and stakeholder perceptions are evaluated by checking 
formulary uptake of two recently (2015) launch biosimilars for infliximab – Remsima 
and Inflectra. Results: NICE, SMC, and the NHS in Scotland recently have or are 
known to be working on formal positions on biosimilars. NICE (for STAs) and SMC 
have recently decided not to appraise biosimilars and there were no questions from 
the AWMSG for the biosimilars it accepted for use recently. However, expected (30%) 
and actual (10%) list-price reductions have not matched. Local discounts, budget 
considerations as well as payer, physician, and patient perception can play a crucial 
role in getting biosimilars on formularies. ConClusions: The number of biosimi-
lars accessing the UK market is rising. By all counts formal HTA assessments are 
not to be regularly expected in the UK, leaving such agencies to focus on innovative 
medicines at a national level. Decision on access to biosimilars in the UK hinges 
crucially on local market issues like price and perception.
PHP256
comParison Between Hta rePorts in Veneto and emilia romagna: 
drUgs assessment decision criteria and Priorities
Bruno GM1, Valentino MC1, Oselin M2, Colombo GL2, Di Matteo S1
1S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, 2University of Pavia, Milan, 
Italy
objeCtives: To review and compare HTA reports produced by two Italian 
Regions: Veneto and Emilia Romagna. To highlight analogies and differences 
between the elements evaluated in the reports and the outcomes of the assess-
ments made. Methods: A descriptive analysis of HTA reports produced by the 
Coordinamento Regionale Unico sul Farmaco (CRUF) of Veneto and Commissione 
Regionale del Farmaco (CRF) of Emilia Romagna. In order to obtain a direct compari-
son on the assessment methods of the two regions, only reports regarding the same 
active principles were considered. The analysed reports were published between 
2011 and 2014. Coherently with the principle of transparency professed by these HTA 
institutions, all the data included in the analysis were directly obtained from the 
agencies’ websites. Results: For all of the 5 drugs analysed in the reports, Veneto 
and Emilia Romagna considered same elements, such as safety, comparators, indica-
tion, and concluded the identical results about them. Both Regions provided always 
the same efficacy studies; in 2 cases Emilia Romagna evaluated more secondary 
endpoints, while in 1 it considered more studies than Veneto, nevertheless the two 
regions drew equal conclusions about efficacy. Different approaches were taken 
when conducting economic evaluations: both Regions considered drugs’ costs but 
Emilia Romagna, on the contrary of Veneto, never developed neither a budget impact 
analysis nor a target population study. Finally, in 3 out of 5 cases Commissions 
drew different conclusions about the selection of patients to which give the drug 
to or whether including or not the drug in the Prontuario Terapeutico Regionale 
(PTR). ConClusions: Divergences in final decisions highlight different priorities 
of each HTA region regarding the criteria used to make evaluations. Because of the 
goal of transparency both Regions have, the lack of evidence of mechanisms they 
adopt in taking assessments should be filled.
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objeCtives: The newly established French Economic Evaluation and Public Health 
Commission (CEESP) provides recommendations and opinions to decision mak-
ers about economic evaluations (EEs) for innovative and expensive treatments. 
In this context, our aim was to compare the differences between EEs conducted 
in three major health authorities in Europe: SMC, NICE and CEESP. Methods: 
Using the Prismaccess database, we identified all technology appraisals (TAs), 
excluding vaccines, published by CEESP prior to June 2015. For these products, 
we sought corresponding guidance published by English and Scottish agencies 
(NICE, SMC) and compared methodology and results of the EEs. Data collected 
for each TA included: study population, comparator, type of analysis, model, time 
horizon, perspective, clinical and utility data, costs and results. Results: We 
Prior to any indication of a potential privacy risk, 31% of consumers indicate they 
would be very likely to download an EHR mobile application (rated 6 or 7 on 7-point 
Likert scale; 4.0 mean). This likelihood decreased with age. After introducing variable 
levels of privacy risk, and within the multivariate framework, age and educational 
level revealed inverse statistical associations with risk tolerance (greater age and 
educational achievement were less likely to download the hypothetical app). In 
contrast, higher income levels and higher levels of patient satisfaction with their 
physicians were associated with greater likelihood to download. These results were 
statistically significant at α = 0.05. ConClusions: One in three consumers reports 
they would be very likely to download an EHR mobile application. Younger demo-
graphics are more likely to download the app and are more accepting of risk of those 
data being leaked to a 3rd party. While the likelihood to download the app increases 
with income level, higher levels of education may actually reduce the likelihood 
of downloading. Physician satisfaction is also a driver of increased likelihood to 
download the application.
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objeCtives: 90% of the German population is insured in the statutory health 
insurance which covers nearly all healthcare services with only little co-payments. 
German health insurance claims data therefore constitute an important basis for 
real world evidence (RWE) on morbidity and healthcare costs. Aim of this study was 
to investigate to which extent RWE was used for estimation of prevalence and inci-
dence in German AMNOG assessments since introduction 4 years ago and its impact 
on price discounts. Methods: German AMNOG dossiers with published benefit 
assessments until March 2015 were evaluated. They were screened for use of RWE 
in assessing prevalence and incidence and also target populations. After descrip-
tion and discussion of methods and data sources used, statistics were applied to 
explore a potential influence of use and quality of RWE data on magnitude of price 
discounts. Results: 134 AMNOG dossiers were included of which 50% utilized 
RWE to assess prevalence, incidence, and target populations. German claims data 
were employed in 16 dossiers (24%), registry data in 7 dossiers (10%), and other data 
sources like Delphi panels in 49 dossiers (73%). Claims data were mostly applied 
for prevalence estimations of both the underlying disease and target populations. 
Compared to numbers stated by the Federal Joint Committee, target populations 
were accepted as reported in 56% and underrated numbers in 44% of those dossiers 
specifically using claims data. Price negotiations were completed for 80 AMNOG 
assessments. A t-test evaluating the association between use of RWE and negotiated 
price discounts indicated that price discounts were lower in assessments that did 
incorporate RWE data (p= 0.049). ConClusions: German claims data constitute 
a valuable and valid data source for assessing epidemiologic evidence in German 
AMNOG assessments and can be a valuable tool for subsequent price negotiations.
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objeCtives: To assess guidance for using single-arm studies in indirect compari-
sons (ICs) to support health technology assessment submissions. ICs enable com-
parison of different treatments using data from separate studies. The published 
methodology for conducting ICs outline the requirement for multiple arm studies 
to form connections between direct and indirect evidence. This is not possible when 
trials have single arms, a particular issue for treatments for new indications or 
for rare diseases. Methods: Guidelines were searched for advice on the use of 
single-arm trial data in ICs: National Institute of Health and Care Excellence [NICE], 
Cochrane; Centre for Reviews and Dissemination; and Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses. In addition the NICE website was searched 
for new drug submissions including single-arm studies in ICs. Results: There is 
minimal current guidance for dealing with single-arm studies in ICs. NICE recom-
mends that such analyses should be treated as observational and appropriate steps 
taken to adjust for possible bias. There are very few submissions where single-arm 
trial evidence has been used in an IC. Those that attempted to compare outcomes 
from single-arm studies were mostly in oncology and in many cases the reviewing 
committee had requested this additional information. Cost-effectiveness calcula-
tions using these data were acknowledged as being highly unreliable, even after 
attempts had been made to adjust for possible between-study bias. ConClusions: 
A number of methods could be used to compare results across multiple single-arm 
studies. A Bayesian hierarchical model that includes random effects allowing for 
heterogeneity between studies is a good choice. However, there is a need for clear 
guidance from organisations such as NICE and Cochrane, who provide recommen-
dations on carrying out systematic reviews and indirect comparisons, on this and 
other approaches to synthesising information from single-arm studies.
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objeCtives: In order for NICE to issue final guidance regarding a new or existing 
medicine to the NHS, the appeal period for the technology appraisal has to have 
passed and if an appeal is submitted, it has to be resolved. The Appeal Panel con-
siders appeals which meet one or more of the grounds of appeal defined by NICE. 
The objective of this study was to identify the past appeal decisions and report 
the respective results. Methods: A review of past NICE appeals decisions was 
conducted via a comprehensive search of the NICE website. Published technology 
appraisals in which appeals were lodged were identified. Only completed appraisals 
